Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with a closing price of 21.8 yuan on November 10, 2025, reflecting a 0.65% rise, despite a net outflow of main funds [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Market Position - Meihao Medical's total market capitalization is 12.401 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan, ranking 27th in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) is 44.67, which is lower than the industry average of 62.58, while the price-to-book ratio (P/B) stands at 3.35, also below the industry average of 4.04 [3]. Fund Flow Analysis - On November 10, 2025, the main funds experienced a net outflow of 4.2463 million yuan, accounting for 5.82% of the total transaction amount, while retail investors saw a net inflow of 3.3461 million yuan, representing 4.58% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant outflows from main funds on several days, indicating a mixed sentiment among investors [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, and the average target price set by institutions is 25.2 yuan [4].
股票行情快报：美好医疗（301363）11月10日主力资金净卖出424.63万元